Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 84

1.

Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency ex vivo without T cell activation.

Gunst JD, Kjær K, Olesen R, Rasmussen TA, Østergaard L, Denton PW, Søgaard OS, Tolstrup M.

J Virus Erad. 2019 Sep 18;5(3):133-137.

PMID:
31700656
2.

Fimepinostat, a novel dual inhibitor of HDAC and PI3K, effectively reverses HIV-1 latency ex vivo without T cell activation.

Gunst JD, Kjær K, Olesen R, Rasmussen TA, Østergaard L, Denton PW, Søgaard OS, Tolstrup M.

J Virus Erad. 2019 Sep 18;5(3):133-137.

PMID:
31700655
3.

Impacts of HIV Cure Interventions on Viral Reservoirs in Tissues.

Denton PW, Søgaard OS, Tolstrup M.

Front Microbiol. 2019 Aug 21;10:1956. doi: 10.3389/fmicb.2019.01956. eCollection 2019. Review.

4.

TLR9 agonist MGN1703 enhances B cell differentiation and function in lymph nodes.

Schleimann MH, Kobberø ML, Vibholm LK, Kjær K, Giron LB, Busman-Sahay K, Chan CN, Nekorchuk M, Schmidt M, Wittig B, Damsgaard TE, Ahlburg P, Hellfritzsch MB, Zuwala K, Rothemejer FH, Olesen R, Schommers P, Klein F, Dweep H, Kossenkov A, Nyengaard JR, Estes JD, Abdel-Mohsen M, Østergaard L, Tolstrup M, Søgaard OS, Denton PW.

EBioMedicine. 2019 Jul;45:328-340. doi: 10.1016/j.ebiom.2019.07.005. Epub 2019 Jul 9.

5.

DC-based immunotherapy as strategy to purge the HIV reservoir?

Søgaard OS.

EBioMedicine. 2019 May;43:16-17. doi: 10.1016/j.ebiom.2019.04.013. Epub 2019 Apr 10. No abstract available.

6.

Effects of 24-week Toll-like receptor 9 agonist treatment in HIV type 1+ individuals.

Vibholm LK, Konrad CV, Schleimann MH, Frattari G, Winckelmann A, Klastrup V, Jensen NM, Jensen SS, Schmidt M, Wittig B, Zuwala K, Mack K, Olesen R, Hua S, Lichterfeld M, Østergaard L, Denton PW, Tolstrup M, Søgaard OS.

AIDS. 2019 Jul 1;33(8):1315-1325. doi: 10.1097/QAD.0000000000002213.

PMID:
30932955
7.

Recommendations for analytical antiretroviral treatment interruptions in HIV research trials-report of a consensus meeting.

Julg B, Dee L, Ananworanich J, Barouch DH, Bar K, Caskey M, Colby DJ, Dawson L, Dong KL, Dubé K, Eron J, Frater J, Gandhi RT, Geleziunas R, Goulder P, Hanna GJ, Jefferys R, Johnston R, Kuritzkes D, Li JZ, Likhitwonnawut U, van Lunzen J, Martinez-Picado J, Miller V, Montaner LJ, Nixon DF, Palm D, Pantaleo G, Peay H, Persaud D, Salzwedel J, Salzwedel K, Schacker T, Sheikh V, Søgaard OS, Spudich S, Stephenson K, Sugarman J, Taylor J, Tebas P, Tiemessen CT, Tressler R, Weiss CD, Zheng L, Robb ML, Michael NL, Mellors JW, Deeks SG, Walker BD.

Lancet HIV. 2019 Apr;6(4):e259-e268. doi: 10.1016/S2352-3018(19)30052-9. Epub 2019 Mar 15. Review.

PMID:
30885693
8.

In-vivo administration of histone deacetylase inhibitors does not impair natural killer cell function in HIV+ individuals.

Garrido C, Tolstrup M, Søgaard OS, Rasmussen TA, Allard B, Soriano-Sarabia N, Archin NM, Margolis DM.

AIDS. 2019 Mar 15;33(4):605-613. doi: 10.1097/QAD.0000000000002112.

PMID:
30830886
9.

Characterization of Intact Proviruses in Blood and Lymph Node from HIV-Infected Individuals Undergoing Analytical Treatment Interruption.

Vibholm LK, Lorenzi JCC, Pai JA, Cohen YZ, Oliveira TY, Barton JP, Garcia Noceda M, Lu CL, Ablanedo-Terrazas Y, Del Rio Estrada PM, Reyes-Teran G, Tolstrup M, Denton PW, Damsgaard T, Søgaard OS, Nussenzweig MC.

J Virol. 2019 Apr 3;93(8). pii: e01920-18. doi: 10.1128/JVI.01920-18. Print 2019 Apr 15.

10.

Characterization of the HIV-1 transcription profile after romidepsin administration in ART-suppressed individuals.

Moron-Lopez S, Kim P, Søgaard OS, Tolstrup M, Wong JK, Yukl SA.

AIDS. 2019 Mar 1;33(3):425-431. doi: 10.1097/QAD.0000000000002083.

PMID:
30531314
11.

Clinical Interventions in HIV Cure Research.

Rasmussen TA, Søgaard OS.

Adv Exp Med Biol. 2018;1075:285-318. doi: 10.1007/978-981-13-0484-2_12. Review.

PMID:
30030798
12.

Differences in antiretroviral regimens do not impact safety or level of latency reversal in persons receiving romidepsin.

Jørgensen S, Leth S, Sommerfelt M, Østergaard L, Tolstrup M, Søgaard OS.

AIDS. 2018 Jul 31;32(12):1729-1731. doi: 10.1097/QAD.0000000000001904. No abstract available.

PMID:
30001247
13.

Genetic characterization of the HIV-1 reservoir after Vacc-4x and romidepsin therapy in HIV-1-infected individuals.

Winckelmann A, Morcilla V, Shao W, Schleimann MH, Hojen JF, Schlub TE, Denton PW, Østergaard L, Søgaard OS, Tolstrup M, Palmer S.

AIDS. 2018 Aug 24;32(13):1793-1802. doi: 10.1097/QAD.0000000000001861.

14.

Treatment of HIV-Infected Individuals with the Histone Deacetylase Inhibitor Panobinostat Results in Increased Numbers of Regulatory T Cells and Limits Ex Vivo Lipopolysaccharide-Induced Inflammatory Responses.

Brinkmann CR, Højen JF, Rasmussen TA, Kjær AS, Olesen R, Denton PW, Østergaard L, Ouyang Z, Lichterfeld M, Yu X, Søgaard OS, Dinarello C, Tolstrup M.

mSphere. 2018 Feb 14;3(1). pii: e00616-17. doi: 10.1128/mSphere.00616-17. eCollection 2018 Jan-Feb.

15.

Cellular immunogenicity of human papillomavirus vaccines Cervarix and Gardasil in adults with HIV infection.

Zurek Munk-Madsen M, Toft L, Kube T, Richter R, Ostergaard L, Søgaard OS, Tolstrup M, Kaufmann AM.

Hum Vaccin Immunother. 2018 Apr 3;14(4):909-916. doi: 10.1080/21645515.2017.1407896. Epub 2017 Dec 20.

16.

Estimating Initial Viral Levels during Simian Immunodeficiency Virus/Human Immunodeficiency Virus Reactivation from Latency.

Pinkevych M, Fennessey CM, Cromer D, Tolstrup M, Søgaard OS, Rasmussen TA, Keele BF, Davenport MP.

J Virol. 2018 Jan 2;92(2). pii: e01667-17. doi: 10.1128/JVI.01667-17. Print 2018 Jan 15.

17.

Sequential Vacc-4x and romidepsin during combination antiretroviral therapy (cART): Immune responses to Vacc-4x regions on p24 and changes in HIV reservoirs.

Tapia G, Højen JF, Ökvist M, Olesen R, Leth S, Nissen SK, VanBelzen DJ, O'Doherty U, Mørk A, Krogsgaard K, Søgaard OS, Østergaard L, Tolstrup M, Pantaleo G, Sommerfelt MA.

J Infect. 2017 Dec;75(6):555-571. doi: 10.1016/j.jinf.2017.09.004. Epub 2017 Sep 14.

PMID:
28917661
18.

HDAC inhibition induces HIV-1 protein and enables immune-based clearance following latency reversal.

Wu G, Swanson M, Talla A, Graham D, Strizki J, Gorman D, Barnard RJ, Blair W, Søgaard OS, Tolstrup M, Østergaard L, Rasmussen TA, Sekaly RP, Archin NM, Margolis DM, Hazuda DJ, Howell BJ.

JCI Insight. 2017 Aug 17;2(16). pii: 92901. doi: 10.1172/jci.insight.92901. eCollection 2017 Aug 17.

19.

The TLR9 agonist MGN1703 triggers a potent type I interferon response in the sigmoid colon.

Krarup AR, Abdel-Mohsen M, Schleimann MH, Vibholm L, Engen PA, Dige A, Wittig B, Schmidt M, Green SJ, Naqib A, Keshavarzian A, Deng X, Olesen R, Petersen AM, Benfield T, Østergaard L, Rasmussen TA, Agnholt J, Nyengaard JR, Landay A, Søgaard OS, Pillai SK, Tolstrup M, Denton PW.

Mucosal Immunol. 2018 Mar;11(2):449-461. doi: 10.1038/mi.2017.59. Epub 2017 Aug 2.

20.

Anti-HIV-1 ADCC Antibodies following Latency Reversal and Treatment Interruption.

Lee WS, Kristensen AB, Rasmussen TA, Tolstrup M, Østergaard L, Søgaard OS, Wines BD, Hogarth PM, Reynaldi A, Davenport MP, Emery S, Amin J, Cooper DA, Kan VL, Fox J, Gruell H, Parsons MS, Kent SJ.

J Virol. 2017 Jul 12;91(15). pii: e00603-17. doi: 10.1128/JVI.00603-17. Print 2017 Aug 1.

21.

Beyond antiretroviral therapy: early interventions to control HIV-1 infection.

Gunst JD, Tolstrup M, Søgaard OS.

AIDS. 2017 Jul 31;31(12):1665-1667. doi: 10.1097/QAD.0000000000001524. No abstract available.

PMID:
28463884
22.

Short-Course Toll-Like Receptor 9 Agonist Treatment Impacts Innate Immunity and Plasma Viremia in Individuals With Human Immunodeficiency Virus Infection.

Vibholm L, Schleimann MH, Højen JF, Benfield T, Offersen R, Rasmussen K, Olesen R, Dige A, Agnholt J, Grau J, Buzon M, Wittig B, Lichterfeld M, Petersen AM, Deng X, Abdel-Mohsen M, Pillai SK, Rutsaert S, Trypsteen W, De Spiegelaere W, Vandekerchove L, Østergaard L, Rasmussen TA, Denton PW, Tolstrup M, Søgaard OS.

Clin Infect Dis. 2017 Jun 15;64(12):1686-1695. doi: 10.1093/cid/cix201.

23.

Romidepsin-induced HIV-1 viremia during effective antiretroviral therapy contains identical viral sequences with few deleterious mutations.

Winckelmann A, Barton K, Hiener B, Schlub TE, Shao W, Rasmussen TA, Østergaard L, Søgaard OS, Tolstrup M, Palmer S.

AIDS. 2017 Mar 27;31(6):771-779. doi: 10.1097/QAD.0000000000001400.

24.

Infective endocarditis in patients receiving chronic hemodialysis: A 21-year observational cohort study in Denmark.

Ludvigsen LU, Dalgaard LS, Wiggers H, Jensen-Fangel S, Jespersen B, Ellermann-Eriksen S, Østergaard L, Søgaard OS.

Am Heart J. 2016 Dec;182:36-43. doi: 10.1016/j.ahj.2016.08.012. Epub 2016 Aug 31.

PMID:
27914498
25.

Risk and prognosis of bacteremia and fungemia among first-time kidney transplant recipients: a population-based cohort study.

Skov Dalgaard L, Nørgaard M, Povlsen JV, Morrissey O, Jespersen B, Jensen-Fangel S, Østergaard LJ, Schønheyder HC, Søgaard OS.

Infect Dis (Lond). 2017 Apr;49(4):286-295. doi: 10.1080/23744235.2016.1248483. Epub 2016 Nov 8.

PMID:
27822975
26.

Combined effect of Vacc-4x, recombinant human granulocyte macrophage colony-stimulating factor vaccination, and romidepsin on the HIV-1 reservoir (REDUC): a single-arm, phase 1B/2A trial.

Leth S, Schleimann MH, Nissen SK, Højen JF, Olesen R, Graversen ME, Jørgensen S, Kjær AS, Denton PW, Mørk A, Sommerfelt MA, Krogsgaard K, Østergaard L, Rasmussen TA, Tolstrup M, Søgaard OS.

Lancet HIV. 2016 Oct;3(10):e463-72. doi: 10.1016/S2352-3018(16)30055-8. Epub 2016 Jul 7.

PMID:
27658863
27.

Broad activation of latent HIV-1 in vivo.

Barton K, Hiener B, Winckelmann A, Rasmussen TA, Shao W, Byth K, Lanfear R, Solomon A, McMahon J, Harrington S, Buzon M, Lichterfeld M, Denton PW, Olesen R, Østergaard L, Tolstrup M, Lewin SR, Søgaard OS, Palmer S.

Nat Commun. 2016 Sep 8;7:12731. doi: 10.1038/ncomms12731.

28.

Correction: HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days-Implications for HIV Remission.

Pinkevych M, Cromer D, Tolstrup M, Grimm AJ, Cooper DA, Lewin SR, Søgaard OS, Rasmussen TA, Kent SJ, Kelleher AD, Davenport MP.

PLoS Pathog. 2016 Aug 25;12(8):e1005745. doi: 10.1371/journal.ppat.1005745. eCollection 2016 Aug.

29.

Modeling of Experimental Data Supports HIV Reactivation from Latency after Treatment Interruption on Average Once Every 5-8 Days.

Pinkevych M, Kent SJ, Tolstrup M, Lewin SR, Cooper DA, Søgaard OS, Rasmussen TA, Kelleher AD, Cromer D, Davenport MP.

PLoS Pathog. 2016 Aug 25;12(8):e1005740. doi: 10.1371/journal.ppat.1005740. eCollection 2016 Aug. No abstract available.

30.

Immune checkpoints and the HIV-1 reservoir: proceed with caution.

Olesen R, Leth S, Nymann R, Østergaard L, Søgaard OS, Denton PW, Tolstrup M.

J Virus Erad. 2016 Jul 1;2(3):183-6. No abstract available.

31.

Risk and outcome of pyelonephritis among renal transplant recipients.

Graversen ME, Dalgaard LS, Jensen-Fangel S, Jespersen B, Østergaard L, Søgaard OS.

BMC Infect Dis. 2016 Jun 10;16:264. doi: 10.1186/s12879-016-1608-x.

32.

Risk and Prognosis of Bacteremia and Fungemia Among Peritoneal Dialysis Patients: A Population-Based Cohort Study.

Dalgaard LS, Nørgaard M, Povlsen JV, Jespersen B, Jensen-Fangel S, Ellermann-Eriksen S, Østergaard L, Schønheyder HC, Søgaard OS.

Perit Dial Int. 2016 11-12;36(6):647-654. Epub 2016 May 4.

33.

The potential role for romidepsin as a component in early HIV-1 curative efforts.

Gunst JD, Tolstrup M, Rasmussen TA, Søgaard OS.

Expert Rev Anti Infect Ther. 2016;14(5):447-50. doi: 10.1586/14787210.2016.1164031. Epub 2016 Mar 24. No abstract available.

PMID:
26953620
34.

A Novel Toll-Like Receptor 9 Agonist, MGN1703, Enhances HIV-1 Transcription and NK Cell-Mediated Inhibition of HIV-1-Infected Autologous CD4+ T Cells.

Offersen R, Nissen SK, Rasmussen TA, Østergaard L, Denton PW, Søgaard OS, Tolstrup M.

J Virol. 2016 Apr 14;90(9):4441-4453. doi: 10.1128/JVI.00222-16. Print 2016 May.

35.

Using animal models to overcome temporal, spatial and combinatorial challenges in HIV persistence research.

Denton PW, Søgaard OS, Tolstrup M.

J Transl Med. 2016 Feb 9;14:44. doi: 10.1186/s12967-016-0807-y. Review.

36.

Administration of Panobinostat Is Associated with Increased IL-17A mRNA in the Intestinal Epithelium of HIV-1 Patients.

Bjerg Christensen A, Dige A, Vad-Nielsen J, Brinkmann CR, Bendix M, Østergaard L, Tolstrup M, Søgaard OS, Rasmussen TA, Randel Nyengaard J, Agnholt J, Denton PW.

Mediators Inflamm. 2015;2015:120605. doi: 10.1155/2015/120605. Epub 2015 Dec 1.

37.

Reversal of Latency as Part of a Cure for HIV-1.

Rasmussen TA, Tolstrup M, Søgaard OS.

Trends Microbiol. 2016 Feb;24(2):90-97. doi: 10.1016/j.tim.2015.11.003. Epub 2015 Dec 11. Review.

PMID:
26690612
38.

HIV-1 transcriptional activity during frequent longitudinal sampling in aviremic patients on antiretroviral therapy.

Leth S, Nymann R, Jørgensen S, Olesen R, Rasmussen TA, Østergaard L, Denton PW, Tolstrup M, Søgaard OS.

AIDS. 2016 Mar 13;30(5):713-21. doi: 10.1097/QAD.0000000000000974.

PMID:
26595541
39.

Panobinostat, a histone deacetylase inhibitor, for latent-virus reactivation in HIV-infected patients on suppressive antiretroviral therapy: a phase 1/2, single group, clinical trial.

Rasmussen TA, Tolstrup M, Brinkmann CR, Olesen R, Erikstrup C, Solomon A, Winckelmann A, Palmer S, Dinarello C, Buzon M, Lichterfeld M, Lewin SR, Østergaard L, Søgaard OS.

Lancet HIV. 2014 Oct;1(1):e13-21. doi: 10.1016/S2352-3018(14)70014-1. Epub 2014 Sep 15.

PMID:
26423811
40.

The Depsipeptide Romidepsin Reverses HIV-1 Latency In Vivo.

Søgaard OS, Graversen ME, Leth S, Olesen R, Brinkmann CR, Nissen SK, Kjaer AS, Schleimann MH, Denton PW, Hey-Cunningham WJ, Koelsch KK, Pantaleo G, Krogsgaard K, Sommerfelt M, Fromentin R, Chomont N, Rasmussen TA, Østergaard L, Tolstrup M.

PLoS Pathog. 2015 Sep 17;11(9):e1005142. doi: 10.1371/journal.ppat.1005142. eCollection 2015 Sep.

41.

Innate Immune Activity Correlates with CD4 T Cell-Associated HIV-1 DNA Decline during Latency-Reversing Treatment with Panobinostat.

Olesen R, Vigano S, Rasmussen TA, Søgaard OS, Ouyang Z, Buzon M, Bashirova A, Carrington M, Palmer S, Brinkmann CR, Yu XG, Østergaard L, Tolstrup M, Lichterfeld M.

J Virol. 2015 Oct;89(20):10176-89. doi: 10.1128/JVI.01484-15. Epub 2015 Jul 29.

42.

Does pneumococcal vaccination prevent myocardial infarction and stroke in elderly adults?

Søgaard OS.

Open Heart. 2015 Jul 21;2(1):e000306. doi: 10.1136/openhrt-2015-000306. eCollection 2015. No abstract available.

43.

HIV Reactivation from Latency after Treatment Interruption Occurs on Average Every 5-8 Days--Implications for HIV Remission.

Pinkevych M, Cromer D, Tolstrup M, Grimm AJ, Cooper DA, Lewin SR, Søgaard OS, Rasmussen TA, Kent SJ, Kelleher AD, Davenport MP.

PLoS Pathog. 2015 Jul 2;11(7):e1005000. doi: 10.1371/journal.ppat.1005000. eCollection 2015 Jul. Erratum in: PLoS Pathog. 2016 Aug;12(8):e1005745.

44.

Activation of latent human immunodeficiency virus by the histone deacetylase inhibitor panobinostat: a pilot study to assess effects on the central nervous system.

Rasmussen TA, Tolstrup M, Møller HJ, Brinkmann CR, Olesen R, Erikstrup C, Laursen AL, Østergaard L, Søgaard OS.

Open Forum Infect Dis. 2015 Mar 30;2(1):ofv037. doi: 10.1093/ofid/ofv037. eCollection 2015 Jan.

45.

Risk and Prognosis of Bloodstream Infections among Patients on Chronic Hemodialysis: A Population-Based Cohort Study.

Skov Dalgaard L, Nørgaard M, Jespersen B, Jensen-Fangel S, Østergaard LJ, Schønheyder HC, Søgaard OS.

PLoS One. 2015 Apr 24;10(4):e0124547. doi: 10.1371/journal.pone.0124547. eCollection 2015.

46.

Histone deacetylase inhibitor romidepsin inhibits de novo HIV-1 infections.

Jønsson KL, Tolstrup M, Vad-Nielsen J, Kjær K, Laustsen A, Andersen MN, Rasmussen TA, Søgaard OS, Østergaard L, Denton PW, Jakobsen MR.

Antimicrob Agents Chemother. 2015 Jul;59(7):3984-94. doi: 10.1128/AAC.00574-15. Epub 2015 Apr 20.

47.

Interleukin-37 Expression Is Increased in Chronic HIV-1-Infected Individuals and Is Associated with Inflammation and the Size of the Total Viral Reservoir.

Højen JF, Rasmussen TA, Andersen KL, Winckelmann AA, Laursen RR, Gunst JD, Møller HJ, Fujita M, Østergaard L, Søgaard OS, Dinarello CA, Tolstrup M.

Mol Med. 2015 Apr 14;21:337-45. doi: 10.2119/molmed.2015.00031.

48.

The histone deacetylase inhibitor panobinostat lowers biomarkers of cardiovascular risk and inflammation in HIV patients.

Høgh Kølbæk Kjær AS, Brinkmann CR, Dinarello CA, Olesen R, Østergaard L, Søgaard OS, Tolstrup M, Rasmussen TA.

AIDS. 2015 Jun 19;29(10):1195-200. doi: 10.1097/QAD.0000000000000678.

PMID:
25870990
49.

Risk and prognosis of Staphylococcus aureus bacteremia among individuals with and without end-stage renal disease: a Danish, population-based cohort study.

Nielsen LH, Jensen-Fangel S, Benfield T, Skov R, Jespersen B, Larsen AR, Østergaard L, Støvring H, Schønheyder HC, Søgaard OS.

BMC Infect Dis. 2015 Jan 8;15:6. doi: 10.1186/s12879-014-0740-8.

50.

[Oral ulcer as primary manifestation of HIV infection in an 80-year-old man].

Ludvigsen LU, Søgaard OS.

Ugeskr Laeger. 2014 Dec 15;176(25A). pii: V08120498. Danish.

PMID:
25497664

Supplemental Content

Loading ...
Support Center